Table 2.
Functional enrichment analysis results for KEGG pathways [64] of the top 200 genes of the proposed method on GBM dataset
| Pathway | Count | % | p-value | Pathway | Count | % | p-value |
|---|---|---|---|---|---|---|---|
| Pathways in cancer | 48 | 24.12 | 1.44e-24 | Leukocyte transendothelial migration | 11 | 5.53 | 1.44e-04 |
| Focal adhesion | 28 | 14.07 | 5.09e-15 | Apoptosis | 8 | 4.02 | 2.55e-04 |
| Prostate cancer | 20 | 10.05 | 6.97e-15 | Renal cell carcinoma | 8 | 4.02 | 3.43e-04 |
| Glioma | 15 | 7.54 | 3.13e-11 | Gap junction | 9 | 4.52 | 4.20e-04 |
| Pancreatic cancer | 15 | 7.54 | 3.13e-11 | Melanogenesis | 9 | 4.52 | 9.88e-04 |
| Colorectal cancer | 14 | 7.04 | 2.35e-10 | Small cell lung cancer | 8 | 4.02 | 1.73e-03 |
| Melanoma | 14 | 7.04 | 1.41e-09 | Wnt signaling pathway | 10 | 5.03 | 2.06e-03 |
| Endometrial cancer | 12 | 6.03 | 5.50e-09 | Hedgehog signaling pathway | 5 | 2.51 | 2.08e-03 |
| p53 signaling pathway | 13 | 6.53 | 8.11e-09 | Natural killer cell mediated cytotoxicity | 9 | 4.52 | 3.50e-03 |
| Non-small cell lung cancer | 12 | 6.03 | 1.26e-08 | Chemokine signaling pathway | 11 | 5.53 | 4.82e-03 |
| Chronic myeloid leukemia | 13 | 6.53 | 1.90e-08 | Endocytosis | 13 | 6.53 | 6.63e-03 |
| Neurotrophin signaling pathway | 15 | 7.54 | 1.31e-07 | Fc gamma R-mediated phagocytosis | 7 | 3.52 | 7.40e-03 |
| Regulation of actin cytoskeleton | 18 | 9.05 | 1.26e-06 | Jak-STAT signaling pathway | 9 | 4.52 | 9.78e-03 |
| ErbB signaling pathway | 12 | 6.03 | 1.38e-06 | Mismatch repair | 4 | 2.01 | 1.11e-02 |
| Acute myeloid leukemia | 10 | 5.03 | 1.69e-06 | Calcium signaling pathway | 10 | 5.03 | 1.12e-02 |
| mTOR signaling pathway | 10 | 5.03 | 2.29e-06 | B cell receptor signaling pathway | 6 | 3.02 | 1.34e-02 |
| Cell cycle | 13 | 6.53 | 7.91e-06 | Adipocytokine signaling pathway | 6 | 3.02 | 1.42e-02 |
| Fc epsilon RI signaling pathway | 10 | 5.03 | 8.92e-06 | T cell receptor signaling pathway | 7 | 3.52 | 1.90e-02 |
| Adherens junction | 10 | 5.03 | 1.28e-05 | Cytokine-cytokine receptor interaction | 11 | 5.53 | 1.97e-02 |
| Bladder cancer | 8 | 4.02 | 1.67e-05 | Thyroid cancer | 4 | 2.01 | 2.10e-02 |
| Insulin signaling pathway | 13 | 6.53 | 2.36e-05 | Tight junction | 8 | 4.02 | 2.24e-02 |
| VEGF signaling pathway | 9 | 4.52 | 3.07e-05 | Phosphatidylinositol signaling system | 6 | 3.02 | 5.07e-02 |
| MAPK signaling pathway | 17 | 8.54 | 6.19e-05 | Toll-like receptor signaling pathway | 6 | 3.02 | 6.67e-02 |
| GnRH signaling pathway | 10 | 5.03 | 9.50e-05 | Notch signaling pathway | 4 | 2.01 | 7.52e-02 |
| Basal cell carcinoma | 8 | 4.02 | 1.19e-04 | TGF-beta signaling pathway | 5 | 2.51 | 9.39e-02 |
The pathways are sorted by their enrichment p-values